Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
C 202.85 1.97% 3.92
VRTX closed up 1.97 percent on Tuesday, July 27, 2021, on 74 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Jul 28
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical VRTX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
50 DMA Resistance Bearish 1.97%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.97%
20 DMA Support Bullish 1.97%
Bollinger Band Squeeze Range Contraction 1.97%
Multiple of Ten Bearish Other 1.97%
Older End-of-Day Signals for VRTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Upper Bollinger Band Resistance about 9 hours ago
Up 2% about 10 hours ago
Up 1 ATR about 10 hours ago
Rose Above Previous Day's High about 10 hours ago
60 Minute Opening Range Breakout about 10 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vertex Pharmaceuticals Incorporated Description

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: S&P 500 Nasdaq 100 Chemical Compounds Organic Compounds Autoimmune Disease Infection Influenza Cystic Fibrosis Serious Diseases Hepatitis C Breakthrough Therapy Hepatitis C Virus Treatment Of Autoimmune Disease HCV Janssen Pharmaceutica Cyclopropanes Organofluorides Treatment Of Cystic Fibrosis Genotype HCV Infection Vertex Pharmaceuticals

Is VRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 283.45
52 Week Low 185.325
Average Volume 2,345,558
200-Day Moving Average 216.23
50-Day Moving Average 201.63
20-Day Moving Average 199.17
10-Day Moving Average 199.06
Average True Range 4.11
ADX 12.77
+DI 27.80
-DI 17.26
Chandelier Exit (Long, 3 ATRs) 192.10
Chandelier Exit (Short, 3 ATRs) 203.36
Upper Bollinger Bands 203.19
Lower Bollinger Band 195.15
Percent B (%b) 0.96
BandWidth 4.04
MACD Line -0.14
MACD Signal Line -0.74
MACD Histogram 0.5998
Fundamentals Value
Market Cap 52.75 Billion
Num Shares 260 Million
EPS 10.20
Price-to-Earnings (P/E) Ratio 19.88
Price-to-Sales 9.98
Price-to-Book 7.25
PEG Ratio 0.35
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 209.51
Resistance 3 (R3) 208.85 205.98 208.40
Resistance 2 (R2) 205.98 204.28 206.31 208.03
Resistance 1 (R1) 204.41 203.23 205.20 205.07 207.66
Pivot Point 201.54 201.54 201.93 201.87 201.54
Support 1 (S1) 199.97 199.84 200.76 200.63 198.04
Support 2 (S2) 197.10 198.79 197.43 197.67
Support 3 (S3) 195.53 197.10 197.30
Support 4 (S4) 196.19